#Canada #Annual Meeting #Laval #Bausch Health #Eiry Roberts

Bausch Health Annual Shareholder Meeting 2026

On May 19, 2026, Bausch Health Companies Inc. hosted its Annual Meeting of Shareholders, where the stakeholders actively participated in the crucial process of electing the board of directors. The highlight of the meeting was the election of all 10 nominees, including Dr. Eiry W. Roberts, marking a significant addition to the company's leadership team. Dr. Roberts brings a wealth of experience from her role as the Chief Medical Officer at Neurocrine Biosciences, Inc., where she honed her skills in clinical development and medical strategy. Her election is anticipated to enhance Bausch's focus on scientific innovation and technology.

During the meeting, proxies were counted, and results revealed that Thomas J. Appio, Christian A. Garcia, and Michael Goettler received overwhelming support from shareholders, with each nominee securing over 196 million votes in favor. Other nominees, including Sarah B. Kavanagh and Frank D. Lee, also received substantial votes, though with slightly more dissenting votes from shareholders, highlighting varying levels of confidence in the board.

The meeting analyzed critical agenda items, where shareholders not only confirmed the election results but also approved the compensation packages for the Company's executive officers through a non-binding advisory vote. In addition, the appointment of PricewaterhouseCoopers LLP was sanctioned to continue as the auditors until the next annual meeting in 2027, providing continuity in auditing practices that are crucial for the firm’s transparency and credibility.

The detailed voting results are made available to the U.S. Securities and Exchange Commission (SEC) through a current report on Form 8-K, further reflecting Bausch Health's commitment to keeping its investors informed and engaged. The transparency exhibited during the meeting reinforces the trust between the company and its shareholders, a vital aspect of corporate governance.

Bausch Health continues to make strides in the pharmaceutical industry, focusing on innovation in various healthcare sectors, including gastroenterology, dermatology, and neuroscience, catering to the needs of a diverse patient population. The company aims to ensure that their products foster better health outcomes, aligning with their vision of enriching lives through effective healthcare solutions.

As Bausch Health evolves, stakeholders eagerly await how Dr. Roberts's experience and insights will contribute to shaping the company's future. Her leadership within the Science and Technology Committee is expected to drive fresh perspectives and strategies that align with market demands and scientific advancements.

The 2026 Annual Meeting of Shareholders marks an important milestone for Bausch Health, setting the stage for continuing its commitment to innovation and excellence in healthcare solutions. As the company prepares for its operational and strategic directions, the inclusion of diverse expertise in its board is likely to strengthen its ability to navigate challenges in the ever-changing pharmaceutical landscape.

For additional information about Bausch Health and its recent developments, check their official website at www.bauschhealth.com.